Selected Publications
Kim GYG, Burns J, Freyer CW, Hamilton KW, Frey NV, Gill SI, Hexner EO, Luger SM, Mangan JK, Martin ME, McCurdy SR, Perl AE, Porter DL, Schuster MG, Stadtmauer EA, Loren AW: Risk of invasive fungal infections in patients with high-risk MDS and AML receiving hypomethylating agents Am J Hematol 95 (7): 792-798,2020 .
Frey NV, Gill S, Hexner EO, Schuster S, Nasta S, Loren A, Svoboda J, Stadtmauer E, Landsburg DJ, Mato A, Levine BL, Lacey SF, Melenhorst JJ, Veloso E, Gaymon A, Pequignot E, Shan X, Hwang WT, June CH, Porter DL: Long-Term Outcomes From a Randomized Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells in Relapsed Chronic Lymphocytic Leukemia J Clin Oncol
: JCO1903237,2020 .
Klichinsky M, Ruella M, Shestova O, Lu XM, Best A, Zeeman M, Schmierer M, Gabrusiewicz K, Anderson NR, Petty NE, Cummins KD, Shen F, Shan X, Veliz K, Blouch K, Yashiro-Ohtani Y, Kenderian SS, Kim MY, O'Connor RS, Wallace SR, Kozlowski MS, Marchione DM, Shestov M, Garcia BA, June CH, Gill S.: Human chimeric antigen receptor macrophages for cancer immunotherapy Nat Biotechnol
38 (8): 947-953,2020.
Brian J Ball, Christopher A Famulare, Eytan M Stein, Martin S Tallman, Andriy Derkach, Mikhail Roshal, Saar I Gill, Benjamin M Manning, Jamie Koprivnikar, James McCloskey, Rebecca Testi, Thomas Prebet, Najla H Al Ali, Eric Padron, David A Sallman, Rami S Komrokji, Aaron D Goldberg: Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure Blood Adv
4 (13): 2866-2870,2020.
Freyer CW, Carulli A, Ganetsky A, Hughes ME, Krause TM, Timlin C, Frey NV, Gill SI, Hexner EO, Loren AW, Mangan JK, Martin ME, McCurdy SR, Perl AE, Pratz K, Porter DL, Luger SM.: Venous thromboembolism following pegaspargase in adults receiving antithrombin supplementation Leuk Lymphoma
: 1-8,2020.
Mardiana S, Gill S.: CAR T Cells for Acute Myeloid Leukemia: State of the Art and Future Directions Front Oncol
10 : 697,2020.
Singh N, Lee YG, Shestova O, Ravikumar P, Hayer KE, Hong SJ, Lu XM, Pajarillo R, Agarwal S, Kuramitsu S, Orlando EJ, Mueller KT, Good CR, Berger SL, Shalem O, Weitzman MD, Frey NV, Maude SL, Grupp SA, June CH, Gill S, Ruella M.: Impaired Death Receptor Signaling in Leukemia Causes Antigen-Independent Resistance by Inducing CAR T-cell Dysfunction Cancer Discov
10 (4): 552-567,2020.
Nobles CL, Sherrill-Mix S, Everett JK, Reddy S, Fraietta JA, Porter DL, Frey N, Gill SI, Grupp SA, Maude SL, Siegel DL, Levine BL, June CH, Lacey SF, Melenhorst JJ, Bushman FD.: CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integration J Clin Invest
130 (2): 673-685,2020.
Finck A, Gill SI, June CH.: Cancer immunotherapy comes of age and looks for maturity. Nature Communications 11 (1): 3325,2020.
Frey NV, Shaw PA, Hexner EO, Pequignot E, Gill S, Luger SM, Mangan JK, Loren AW, Perl AE, Maude SL, Grupp SA, Shah NN, Gilmore J, Lacey SF, Melenhorst JJ, Levine BL, June CH, Porter DL.: Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia J Clin Oncol. : JCO1901892,2019.
Academic Contact Information
Room 8-101
Smilow Translational Research Center
3400 Civic Center Blvd
Philadelphia,
PA
19104
Phone: 215-573-4015
Patient appointments: 800-789-7366